TY - JOUR
T1 - Sarcopenia and its impact in head and neck cancer treatment
AU - de Bree, Remco
AU - van Beers, Maartje A
AU - Schaeffers, Anouk W M A
N1 - Funding Information:
The authors received funding for research on sarcopenia in head and neck cancer patients from the Dutch Cancer Society (KWF), the Netherlands Organisation for Health Research and Development (ZonMw) and the Michel Keijzer Fonds, a not for profit fund managed by the Dutch head and neck cancer patient support group (PVHH).
Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - PURPOSE OF REVIEW: The aim of this review is to discuss recent studies on the assessment of sarcopenia and its predictive and prognostic value in head and neck cancer (HNC) patients.RECENT FINDINGS: There is increasing evidence that low skeletal muscle mass (SMM), often named sarcopenia, can easily be assessed on cross-sectional imaging of the head and neck and is associated with chemotherapy (dose limiting) and radiotherapy toxicity and survival.SUMMARY: SMM measurement at the level of the third cervical vertebra (C3) on routine computed tomography and magnetic resonance imaging is easy and robust to perform. Several studies have shown a significantly higher incidence of cisplatin dose limiting toxicity in HNC patients with a low SMM. In HNC patients pretreatment low SMM is associated with acute and late toxicity and adverse events of radiotherapy, complications of major head and neck surgery and decreased disease-specific and overall survival. This information can be used for individualized treatment planning in HNC patients with low SMM.
AB - PURPOSE OF REVIEW: The aim of this review is to discuss recent studies on the assessment of sarcopenia and its predictive and prognostic value in head and neck cancer (HNC) patients.RECENT FINDINGS: There is increasing evidence that low skeletal muscle mass (SMM), often named sarcopenia, can easily be assessed on cross-sectional imaging of the head and neck and is associated with chemotherapy (dose limiting) and radiotherapy toxicity and survival.SUMMARY: SMM measurement at the level of the third cervical vertebra (C3) on routine computed tomography and magnetic resonance imaging is easy and robust to perform. Several studies have shown a significantly higher incidence of cisplatin dose limiting toxicity in HNC patients with a low SMM. In HNC patients pretreatment low SMM is associated with acute and late toxicity and adverse events of radiotherapy, complications of major head and neck surgery and decreased disease-specific and overall survival. This information can be used for individualized treatment planning in HNC patients with low SMM.
KW - Cervical Vertebrae
KW - Head and Neck Neoplasms/pathology
KW - Humans
KW - Muscle, Skeletal/pathology
KW - Prognosis
KW - Sarcopenia/complications
KW - Tomography, X-Ray Computed
KW - toxicity
KW - head and neck cancer
KW - survival
KW - skeletal muscle mass
KW - sarcopenia
UR - http://www.scopus.com/inward/record.url?scp=85125974543&partnerID=8YFLogxK
U2 - 10.1097/MOO.0000000000000792
DO - 10.1097/MOO.0000000000000792
M3 - Review article
C2 - 35255045
SN - 1068-9508
VL - 30
SP - 87
EP - 93
JO - Current Opinion in Otolaryngology & Head and Neck Surgery
JF - Current Opinion in Otolaryngology & Head and Neck Surgery
IS - 2
ER -